These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 2446063)
1. Pathophysiological relevance of serotonin. van Zwieten PA J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S19-25. PubMed ID: 2446063 [TBL] [Abstract][Full Text] [Related]
2. Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs. van Zwieten PA; Blauw GJ; van Brummelen P Clin Physiol Biochem; 1990; 8 Suppl 3():1-18. PubMed ID: 2132170 [TBL] [Abstract][Full Text] [Related]
3. Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs. Robertson JI J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S48-53. PubMed ID: 1717773 [TBL] [Abstract][Full Text] [Related]
4. [Serotoninergic receptors and cardiovascular diseases]. Hong E; Castillo C; Flores E; Mercedes F Gac Med Mex; 1994; 130(3):131-3. PubMed ID: 7657075 [TBL] [Abstract][Full Text] [Related]
5. Serotonin and the vascular system. Role in health and disease, and implications for therapy. Houston DS; Vanhoutte PM Drugs; 1986 Feb; 31(2):149-63. PubMed ID: 3512233 [TBL] [Abstract][Full Text] [Related]
6. Serotonin and preactivated platelets in essential hypertension. Bühler FR; Amstein R; Fetkovska N J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S32-4. PubMed ID: 2446066 [TBL] [Abstract][Full Text] [Related]
7. The role of serotonin in cardiovascular diseases and their treatment. van Zwieten PA; Blauw GJ; van Brummelen P Cardiovasc Drugs Ther; 1990 Dec; 4(6):1443-7. PubMed ID: 2081137 [TBL] [Abstract][Full Text] [Related]